CY1110832T1 - ΠΑΡΑΓΩΓΑ ΠΥΡΡΟΛΟ[3,4-c]ΠΥΡΑΖΟΛΙΟΥ ΔΡΑΣΤΙΚΑ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΚΙΝΑΣΗΣ - Google Patents

ΠΑΡΑΓΩΓΑ ΠΥΡΡΟΛΟ[3,4-c]ΠΥΡΑΖΟΛΙΟΥ ΔΡΑΣΤΙΚΑ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΚΙΝΑΣΗΣ

Info

Publication number
CY1110832T1
CY1110832T1 CY20101100924T CY101100924T CY1110832T1 CY 1110832 T1 CY1110832 T1 CY 1110832T1 CY 20101100924 T CY20101100924 T CY 20101100924T CY 101100924 T CY101100924 T CY 101100924T CY 1110832 T1 CY1110832 T1 CY 1110832T1
Authority
CY
Cyprus
Prior art keywords
pyrozolium
pyrolol
mountains
producers
suspensions
Prior art date
Application number
CY20101100924T
Other languages
English (en)
Inventor
Daniele Fancelli
Barbara Forte
Jurgen Moll
Mario Varasi
Paola Vianello
Original Assignee
Nerviano Medical Sciences S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences S.R.L. filed Critical Nerviano Medical Sciences S.R.L.
Publication of CY1110832T1 publication Critical patent/CY1110832T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Αποκαλύπτονται παράγωγα του πυρρολο [3,4-c]πυραζολίου του τύπου (1) και φαρμακευτικώς παραδεκτά άλατα αυτών, όπως ορίζονται στην προδιαγραφή, μέθοδος παρασκευής τους και φαρμακευτικές συνθέσεις περιέχουσες αυτά. Οι ενώσεις της ευρεσιτεχνίας μπορεί να είναι χρήσιμες, στην θεραπευτική, για την θεραπεία νόσων, σχετιζόμενων με την απορρύθμιση της δραστικότητας της πρωτεϊνοκινάσης, όπως ο καρκίνος.
CY20101100924T 2003-07-09 2010-10-18 ΠΑΡΑΓΩΓΑ ΠΥΡΡΟΛΟ[3,4-c]ΠΥΡΑΖΟΛΙΟΥ ΔΡΑΣΤΙΚΑ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΚΙΝΑΣΗΣ CY1110832T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48581403P 2003-07-09 2003-07-09
EP04763132A EP1644376B1 (en) 2003-07-09 2004-07-08 PYRROLO 3,4-c PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
CY1110832T1 true CY1110832T1 (el) 2015-06-10

Family

ID=34062099

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100924T CY1110832T1 (el) 2003-07-09 2010-10-18 ΠΑΡΑΓΩΓΑ ΠΥΡΡΟΛΟ[3,4-c]ΠΥΡΑΖΟΛΙΟΥ ΔΡΑΣΤΙΚΑ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΚΙΝΑΣΗΣ

Country Status (42)

Country Link
US (2) US7141568B2 (el)
EP (1) EP1644376B1 (el)
JP (1) JP4728232B2 (el)
KR (1) KR101075711B1 (el)
CN (1) CN100564380C (el)
AP (1) AP2214A (el)
AR (1) AR050045A1 (el)
AT (1) ATE480540T1 (el)
AU (1) AU2004255347B2 (el)
BR (1) BRPI0411868B8 (el)
CA (1) CA2531759C (el)
CR (1) CR8171A (el)
CY (1) CY1110832T1 (el)
DE (1) DE602004029045D1 (el)
DK (1) DK1644376T3 (el)
DO (1) DOP2004000949A (el)
EA (1) EA009462B1 (el)
EC (1) ECSP056246A (el)
ES (1) ES2349780T3 (el)
GE (1) GEP20084395B (el)
GT (2) GT200400133A (el)
HK (1) HK1089769A1 (el)
HN (1) HN2004000232A (el)
IL (1) IL172923A (el)
IS (1) IS2843B (el)
MA (1) MA28064A1 (el)
ME (1) MEP51908A (el)
MX (1) MXPA06000362A (el)
MY (1) MY139072A (el)
NO (1) NO332361B1 (el)
NZ (1) NZ544514A (el)
PA (1) PA8606201A1 (el)
PE (1) PE20050325A1 (el)
PL (1) PL1644376T3 (el)
PT (1) PT1644376E (el)
RS (2) RS20060004A (el)
SI (1) SI1644376T1 (el)
TN (1) TNSN06009A1 (el)
TW (1) TWI343382B (el)
UA (1) UA81682C2 (el)
WO (1) WO2005005427A1 (el)
ZA (1) ZA200600095B (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006381B1 (ru) * 2000-08-10 2005-12-29 Фармация Италия С.П.А. Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
CA2539549A1 (en) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
JP2007533753A (ja) * 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド インドール誘導体及びキナーゼ阻害剤としてのその使用
EP1778669A2 (en) * 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
CA2593428C (en) * 2005-01-10 2012-04-17 Pfizer Inc. Pyrrolopyrazoles, potent kinase inhibitors
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200808311A (en) 2006-03-30 2008-02-16 Nerviano Medical Sciences Srl Use of a kinase inhibitor for the treatment of particular resistant tumors
WO2008017465A1 (en) * 2006-08-10 2008-02-14 F. Hoffmann-La Roche Ag Bicyclic lactam derivatives, their manufacture and use as pharmaceutical agents
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
JP2010505961A (ja) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
ATE479432T1 (de) * 2006-11-03 2010-09-15 Nerviano Medical Sciences Srl Verfahren zur verabreichung einer antitumoralen verbindung
AR071780A1 (es) 2008-05-15 2010-07-14 Nerviano Medical Sciences Srl Derivados de carbamoilo de carbonilamino-pirazoles biciclicos como profarmacos
CN102105148B (zh) * 2008-07-24 2013-04-10 内尔维阿诺医学科学有限公司 包含aurora激酶抑制剂和抗肿瘤药的治疗组合
US20110117212A1 (en) * 2008-07-24 2011-05-19 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent
US20100022553A1 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib
JP5738196B2 (ja) 2008-12-22 2015-06-17 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤および抗ｃｄ２０抗体の併用
WO2013088257A1 (en) 2011-12-12 2013-06-20 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors
CN104072498B (zh) * 2013-03-26 2016-12-28 沈阳药科大学 （R）‑N‑[5‑(2‑甲氧基‑2‑苯基乙酰基)‑1,4,5,6‑四氢吡咯并[3,4‑c]吡唑‑3‑基]‑4‑(4‑甲基哌嗪‑1‑基)苯甲酰胺的合成方法
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
CA2953177C (en) 2014-06-23 2019-07-23 Dr. Reddy's Laboratories Ltd. Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain
RU2765718C1 (ru) * 2015-06-15 2022-02-02 Убе Индастриз, Лтд. Замещенное производное дигидропирролопиразола
CN107337674B (zh) * 2016-04-29 2019-09-20 江苏吉贝尔药业股份有限公司 用于dpp-iv抑制剂的四氢吡喃胺衍生物、其药物组合物和制剂以及用途
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
CN113563346A (zh) * 2021-08-19 2021-10-29 守恒(厦门)医疗科技有限公司 吡咯[3,4-c]并吡唑二酰胺类衍生物及其在抗肿瘤药物中的应用
WO2023196959A1 (en) 2022-04-07 2023-10-12 Eli Lilly And Company Process for making a kras g12c inhibitor
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
US20240108618A1 (en) 2022-06-30 2024-04-04 Eli Lilly And Company Kras g12c inhibitor dosing regimens

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717380B1 (fr) * 1994-03-15 1996-04-26 Oreal Compositions cosmétiques contenant un mélange synergétique de polymères conditionneurs.
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
DE19932144A1 (de) * 1999-07-09 2001-01-11 Basf Ag Mikrokapselzubereitungen und Mikrokapseln enthaltende Wasch- und Reinigungsmittel
YU9602A (sh) 1999-08-12 2004-11-25 Pharmacia Italia S.P.A. Derivati 3(5)-amino-pirazola, postupak za njihovu izradu i njihova upotreba kao antitumornih agenasa
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
EA006381B1 (ru) 2000-08-10 2005-12-29 Фармация Италия С.П.А. Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
NZ525892A (en) 2000-11-27 2004-11-26 Pharmacia Italia S Phenylacetamido- pyrazole derivatives their use as antitumor agents and preparation process thereof
MXPA03006478A (es) 2001-01-26 2003-09-22 Pharmacia Italia Spa Derivados de cromano, procedimiento para su preparacion y su uso como agentes antitumorales.
EP1820503B1 (en) 2001-09-26 2012-02-22 Pfizer Italia S.r.l. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
US20060100233A1 (en) 2002-07-25 2006-05-11 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
GT200400133AA (es) 2007-07-10
RS52155B (en) 2012-08-31
TNSN06009A1 (fr) 2007-10-03
RS20060004A (en) 2008-06-05
AR050045A1 (es) 2006-09-27
EP1644376A1 (en) 2006-04-12
JP4728232B2 (ja) 2011-07-20
ATE480540T1 (de) 2010-09-15
TWI343382B (en) 2011-06-11
BRPI0411868B8 (pt) 2021-05-25
PE20050325A1 (es) 2005-05-17
NO332361B1 (no) 2012-09-03
PA8606201A1 (es) 2005-08-04
MXPA06000362A (es) 2006-03-28
IL172923A (en) 2011-09-27
US20060276471A1 (en) 2006-12-07
KR20060033001A (ko) 2006-04-18
AU2004255347A1 (en) 2005-01-20
KR101075711B1 (ko) 2011-10-21
MEP51908A (en) 2011-05-10
EP1644376B1 (en) 2010-09-08
CA2531759C (en) 2013-04-02
NZ544514A (en) 2009-07-31
DE602004029045D1 (de) 2010-10-21
US7582628B2 (en) 2009-09-01
DK1644376T3 (da) 2011-01-03
CN100564380C (zh) 2009-12-02
IS8192A (is) 2005-12-22
IL172923A0 (en) 2006-06-11
US7141568B2 (en) 2006-11-28
NO20060113L (no) 2006-04-05
AP2006003480A0 (en) 2006-02-28
ZA200600095B (en) 2007-01-31
IS2843B (is) 2013-08-15
BRPI0411868A (pt) 2006-08-08
PT1644376E (pt) 2010-09-24
SI1644376T1 (sl) 2010-11-30
US20050032839A1 (en) 2005-02-10
WO2005005427A1 (en) 2005-01-20
MY139072A (en) 2009-08-28
ES2349780T3 (es) 2011-01-11
AU2004255347B2 (en) 2010-04-08
MA28064A1 (fr) 2006-08-01
GEP20084395B (en) 2008-06-10
EA200600209A1 (ru) 2006-06-30
HN2004000232A (es) 2011-01-17
UA81682C2 (en) 2008-01-25
DOP2004000949A (es) 2005-01-15
JP2009513525A (ja) 2009-04-02
PL1644376T3 (pl) 2011-03-31
GT200400133A (es) 2005-04-18
CA2531759A1 (en) 2005-01-20
CR8171A (es) 2006-08-09
CN1820009A (zh) 2006-08-16
AP2214A (en) 2011-03-04
BRPI0411868B1 (pt) 2019-11-12
ECSP056246A (es) 2006-04-19
HK1089769A1 (en) 2006-12-08
TW200510385A (en) 2005-03-16
EA009462B1 (ru) 2007-12-28

Similar Documents

Publication Publication Date Title
CY1110832T1 (el) ΠΑΡΑΓΩΓΑ ΠΥΡΡΟΛΟ[3,4-c]ΠΥΡΑΖΟΛΙΟΥ ΔΡΑΣΤΙΚΑ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΚΙΝΑΣΗΣ
CY1114708T1 (el) Παραγωγα πυραζολο-κιναζολινης, διαδικασια για την παρασκευη τους και η χρηση τους ως αναστολεων κινασης
CY1108246T1 (el) ΠΑΡΑΓΩΓΑ 1Η-ΘΕΙΕΝΟ[2,3-c] ΠΥΡΑΖΟΛΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΗΣ
CY1112084T1 (el) Παραγωγα 5-φαινυλθειαζολης και χρηση ως αναστολεις της κινασης ρi3
CY1115188T1 (el) Πολυκυκλικες ετεροαρυλ-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις του axl
CY1112232T1 (el) Κινολινικα παραγωγα ως αναστολεις φωσφοδιεστερασης
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
MY138352A (en) Benzothiazole derivatives
BG103417A (en) Condensed pyrimidine bicyclic derivatives
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
WO2005105753A8 (en) Naphthalimide derivatives, methods for their production and pharmaceutical compositions therefrom
ATE482955T1 (de) Azabicyclooctan-3-onderivate und deren verwendung
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
DE602004014163D1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
UY26498A1 (es) Pirroles sustituidos
DE60106947D1 (de) Oxindolderivate
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
HK1082727A1 (en) 2" oxo-voruscharin and derivatives thereof
ATE293107T1 (de) Luminacine analoge und deren verwendung
TH78308B (th) อนุพันธ์ของเฮทเทอโรไซคลิคไพราโซลที่ทำปฏิกิริยารวมตัวแล้วในฐานะที่เป็นสารยับยั้งไคเนส
CU23566B7 (es) Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de quinasa
UY28409A1 (es) Derivados de pirrolo (3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparación y composiciones farmaceuticas que los comprenden